{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T21:10:00Z","timestamp":1794258600440,"version":"4.9.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Medical Microbiology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ijmmb.2023.100432","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T11:23:25Z","timestamp":1691493805000},"page":"100432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["Introducing the new face of CLSI M100 in 2023: An explanatory review"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6494-0742","authenticated-orcid":false,"given":"Sumit","family":"Rai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3673-5394","authenticated-orcid":false,"given":"Debabrata","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3561-5307","authenticated-orcid":false,"given":"Nidhima","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijmmb.2023.100432_bib1","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac007","article-title":"Raising the Bar: Improving Antimicrobial Resistance Detection by Clinical Laboratories by Ensuring Use of Current Breakpoints","volume":"9","author":"Simner","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijmmb.2023.100432_bib2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijmmb.2022.09.013","article-title":"Clinical implications of revised piperacillin-tazobactam breakpoints in CLSI M-100 S32","volume":"42","author":"Dash","year":"2023","journal-title":"Indian J Med Microbiol"},{"key":"10.1016\/j.ijmmb.2023.100432_bib3","series-title":"Performance Standards for Antimicrobial Susceptibility Testing","year":"2023"},{"issue":"12","key":"10.1016\/j.ijmmb.2023.100432_bib4","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America Guidance on the Treatment of AmpC \u03b2-Lactamase\u2013Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.ijmmb.2023.100432_bib5","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ijmmb.2023.100432_bib6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/cid\/ciac268","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.ijmmb.2023.100432_bib7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/jac\/dkab344","article-title":"Levofloxacin pharmacodynamics against Stenotrophomonas maltophilia in a neutropenic murine thigh infection model: implications for susceptibility breakpoint revision","volume":"77","author":"Fratoni","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.ijmmb.2023.100432_bib8","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1093\/jac\/dkac018","article-title":"Minocycline pharmacodynamics against Stenotrophomonas maltophilia in the neutropenic murine infection model: implications for susceptibility breakpoints","volume":"77","author":"Fratoni","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijmmb.2023.100432_bib9","series-title":"AST Meeting File Resources","year":"2023"},{"issue":"5","key":"10.1016\/j.ijmmb.2023.100432_bib10","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1128\/jcm.13.5.1000-1003.1981","article-title":"Gentamicin and amikacin disk susceptibility tests with Pseudomonas aeruginosa: definition of minimal inhibitory concentration correlates for susceptible and resistant categories","volume":"13","author":"Barry","year":"1981","journal-title":"J\u00a0Clin Microbiol"},{"issue":"5","key":"10.1016\/j.ijmmb.2023.100432_bib11","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1128\/AAC.24.5.764","article-title":"Error rates associated with the use of recently proposed breakpoints for testing Pseudomonas aeruginosa versus gentamicin, tobramycin, and amikacin by the standardized disk agar diffusion test","volume":"24","author":"Woolfrey","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijmmb.2023.100432_bib12","unstructured":"CLSI. Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters. 5th Ed. CLSI Guideline M23. Wayne PA. Available from: https:\/\/clsi.org."},{"issue":"6","key":"10.1016\/j.ijmmb.2023.100432_bib13","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1086\/520991","article-title":"Back to the Future: Using Aminoglycosides Again and How to Dose Them Optimally","volume":"45","author":"Eliopoulos","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.ijmmb.2023.100432_bib14","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1128\/AAC.39.3.650","article-title":"Experience with a once-daily aminoglycoside program administered to 2,184 adult patients","volume":"39","author":"Nicolau","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijmmb.2023.100432_bib15","series-title":"MIC EUCAST","year":"2023"},{"key":"10.1016\/j.ijmmb.2023.100432_bib16","author":"Ambrose","year":"2019"},{"issue":"7","key":"10.1016\/j.ijmmb.2023.100432_bib17","doi-asserted-by":"crossref","first-page":"ofaa084","DOI":"10.1093\/ofid\/ofaa084","article-title":"Old In Vitro Antimicrobial Breakpoints Are Misleading Stewardship Efforts, Delaying Adoption of Innovative Therapies, and Harming Patients","volume":"7","author":"Ambrose","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.ijmmb.2023.100432_bib18","doi-asserted-by":"crossref","first-page":"ofad058","DOI":"10.1093\/ofid\/ofad058","volume":"10","author":"Sader","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijmmb.2023.100432_bib19","series-title":"Performance Standards for Antimicrobial Susceptibility Testing","year":"2022"},{"issue":"10","key":"10.1016\/j.ijmmb.2023.100432_bib20","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1093\/cid\/ciad012","article-title":"Deconstructing the 2023 Clinical and Laboratory Standards Institute Revised Piperacillin-Tazobactam Breakpoints Against Pseudomonas aeruginosa","volume":"76","author":"Tamma","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijmmb.2023.100432_bib21","author":"Cavalcanti","year":"2010"},{"key":"10.1016\/j.ijmmb.2023.100432_bib22","series-title":"Selective Reporting of Antimicrobial Susceptibility Testing Results: A Primer for Antibiotic Stewardship Programs","year":"2020"},{"key":"10.1016\/j.ijmmb.2023.100432_bib23","series-title":"Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data","year":"2022"},{"key":"10.1016\/j.ijmmb.2023.100432_bib24","author":"Harris","year":"2023"},{"key":"10.1016\/j.ijmmb.2023.100432_bib25","author":"Liu","year":"2023"}],"container-title":["Indian Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085723001482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085723001482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T19:21:22Z","timestamp":1759346482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0255085723001482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":25,"alternative-id":["S0255085723001482"],"URL":"https:\/\/doi.org\/10.1016\/j.ijmmb.2023.100432","relation":{},"ISSN":["0255-0857"],"issn-type":[{"value":"0255-0857","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Introducing the new face of CLSI M100 in 2023: An explanatory review","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Medical Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijmmb.2023.100432","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Indian Association of Medical Microbiologists. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100432"}}